Valeant (VRX) PT, Estimates Cut at BMO Capital; Remains on the Sidelines
Tweet Send to a Friend
BMO Capital analyst Alex Arfaei cut estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $133.00 (from $141.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
